New clinical trial at ECHO for CLL

The Beigene’s CELESTIAL clinical trial for chronic lymphocytic leukemia

This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia.  The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination of venetoclax with obinutuzumab.  Some patients progress on first line treatment and require additional treatment. 

This study offers a new agent, sonrotoclax.  Sonrotoclax is a next generation BCL-2 drug.  The older drug is venetoclax.  Next generation drugs are developed to improve response and limit side effects.  Clinical trials are designed to determine if these newer investigational agents work well in actual patients.  Another facet of this trial is to determine if investigational agent works so well that there is no minimal residual disease, then the length of treatment can be shortened.

Now enrolling patients for this trial. For more information on this, or other clinical trials, please contact:  Dr. Susan Johnson, Director of Research sjohnson@echoct.com / 860-886-8362.